

Ann Marie Navar-Boggan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5362070/publications.pdf>

Version: 2024-02-01

139
papers

5,628
citations

126907

33
h-index

91884

69
g-index

144
all docs

144
docs citations

144
times ranked

8063
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of New Cholesterol Guidelines to a Population-Based Sample. <i>New England Journal of Medicine</i> , 2014, 370, 1422-1431.	27.0	571
2	Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 198-208.	4.4	569
3	Nonmedical Exemptions to School Immunization Requirements. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1757.	7.4	337
4	Apolipoprotein B Particles and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1287.	6.1	299
5	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. <i>Circulation</i> , 2015, 131, 451-458.	1.6	283
6	Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. <i>European Heart Journal</i> , 2017, 38, ehw302.	2.2	276
7	Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0149160.	2.5	170
8	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005562.	2.2	155
9	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011765.	3.7	139
10	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019, 139, 1603-1611.	1.6	115
11	Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research. <i>Journal of the American College of Cardiology</i> , 2019, 73, 317-335.	2.8	114
12	Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. <i>JAMA Cardiology</i> , 2017, 2, 1217.	6.1	100
13	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1424.	7.4	95
14	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	6.1	94
15	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	3.0	90
16	Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e019636.	3.7	80
17	Research Needs to Improve Hypertension Treatment and Control in African Americans. <i>Hypertension</i> , 2016, 68, 1066-1072.	2.7	78
18	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	2.8	72

#	ARTICLE	IF	CITATIONS
19	Trajectories of Non-HDL Cholesterol Across Midlife. <i>Journal of the American College of Cardiology</i> , 2019, 74, 70-79.	2.8	67
20	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1633-1639.	2.8	58
21	Use of Open Access Platforms for Clinical Trial Data. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1283.	7.4	57
22	Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021, 16, e0251963.	2.5	56
23	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , 2017, 193, 84-92.	2.7	55
24	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100250.	3.0	51
25	Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. <i>Hum Vaccin</i> , 2008, 4, 286-291.	2.4	50
26	Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1563.	7.4	49
27	Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	49
28	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	2.8	49
29	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , 2018, 3, 1192.	6.1	48
30	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
31	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. <i>JAMA Cardiology</i> , 2019, 4, 375.	6.1	43
32	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. <i>American Heart Journal</i> , 2022, 247, 15-23.	2.7	40
33	Pediatric-Specific Antimicrobial Susceptibility Data and Empiric Antibiotic Selection. <i>Pediatrics</i> , 2012, 130, e615-e622.	2.1	39
34	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	2.8	39
35	Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age. <i>JAMA Cardiology</i> , 2020, 5, 382.	6.1	35
36	Measuring Immunization Coverage among Preschool Children: Past, Present, and Future Opportunities. <i>Epidemiologic Reviews</i> , 2006, 28, 27-40.	3.5	34

#	ARTICLE	IF	CITATIONS
37	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. <i>Journal of General Internal Medicine</i> , 2020, 35, 1701-1708.	2.6	31
38	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2041.	7.4	30
39	The Evolving Story of Triglycerides and Coronary Heart Disease Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 347.	7.4	30
40	Prenatal Immunization Education. <i>American Journal of Preventive Medicine</i> , 2007, 33, 211-213.	3.0	29
41	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. <i>JAMA Cardiology</i> , 2016, 1, 864.	6.1	29
42	What to say and how to say it. <i>Current Opinion in Cardiology</i> , 2016, 31, 537-544.	1.8	28
43	Machine Learning-Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 844.	6.1	28
44	The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2560-2567.	2.6	26
45	Risk Prediction With Electronic Health Records. <i>JAMA Cardiology</i> , 2016, 1, 976.	6.1	25
46	Fear-Based Medical Misinformation and Disease Prevention. <i>JAMA Cardiology</i> , 2019, 4, 723.	6.1	25
47	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	1.6	25
48	An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 315-322.	2.8	24
49	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004249.	2.2	24
50	Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. <i>Journal of the American Heart Association</i> , 2019, 8, e010241.	3.7	23
51	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	2.2	23
52	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. <i>JAMA Internal Medicine</i> , 2020, 180, 1531.	5.1	23
53	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	22
54	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. <i>Journal of Clinical Lipidology</i> , 2019, 13, 725-734.	1.5	21

#	ARTICLE	IF	CITATIONS
55	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2015, 170, 865-871.	2.7	20
56	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004675.	2.2	20
57	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006548.	2.2	20
58	Simultaneous Single-Particle Tracking and Visualization of Domain Structure on Lipid Monolayers. Langmuir, 2003, 19, 4876-4879.	3.5	19
59	Are Recent Medical Graduates More Skeptical of Vaccines?. Vaccines, 2013, 1, 154-166.	4.4	19
60	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. Journal of the American Heart Association, 2021, 10, e019331.	3.7	19
61	U.S. population at increased risk of severe illness from COVID-19. American Journal of Preventive Cardiology, 2021, 6, 100156.	3.0	19
62	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clinical Infectious Diseases, 2021, 73, 2009-2022.	5.8	19
63	The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. PLoS ONE, 2021, 16, e0254809.	2.5	19
64	Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Progress in Cardiovascular Diseases, 2022, 73, 48-55.	3.1	19
65	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
66	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2019, 214, 113-124.	2.7	17
67	Evaluating the Impact of Interruptive Alerts within a Health System: Use, Response Time, and Cumulative Time Burden. Applied Clinical Informatics, 2019, 10, 909-917.	1.7	17
68	Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization) Tj ETQq0 0 0 rgBT16/Overlock10 Tf 50 2	1.6	17
69	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) Tj ETQq1 1 0.784314 rgBT16/Overlock16	1.6	16
70	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. JAMA Cardiology, 2020, 5, 336.	6.1	16
71	Incremental Benefits of Machine Learningâ€”When Do We Need a Better Mousetrap?. JAMA Cardiology, 2021, 6, 621.	6.1	15
72	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2018, 200, 118-124.	2.7	14

#	ARTICLE	IF	CITATIONS
73	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	3.7	14
74	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. <i>JAMA Cardiology</i> , 2016, 1, 700.	6.1	13
75	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007492.	2.2	13
76	Hypertension Control Among Patients Followed by Cardiologists. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 352-357.	2.2	12
77	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	2.7	12
78	Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. <i>American Heart Journal</i> , 2018, 198, 18-24.	2.7	12
79	Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1117.	6.1	12
80	Disparities in preschool immunization coverage associated with maternal age. <i>Hum Vaccin</i> , 2009, 5, 557-561.	2.4	11
81	Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. <i>American Heart Journal</i> , 2018, 195, 151-152.	2.7	11
82	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e013229.	3.7	11
83	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <i>Journal of the American Heart Association</i> , 2021, 10, e019254.	3.7	11
84	Challenges in Interpreting the Lipid-Lowering Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1549.	7.4	10
85	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol Lowering Therapies Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2021, 6, 92-96.	6.1	10
86	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. <i>European Cardiology Review</i> , 2021, 16, e54.	2.2	10
87	The feasibility and accuracy of evaluating lipid management performance metrics using an electronic health record. <i>American Heart Journal</i> , 2013, 166, 701-708.	2.7	9
88	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	3.7	9
89	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. <i>Journal of Women's Health</i> , 2020, 29, 1091-1100.	3.3	9
90	Variability in performance measures for assessment of hypertension control. <i>American Heart Journal</i> , 2013, 165, 823-827.	2.7	8

#	ARTICLE	IF	CITATIONS
91	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , 2020, 225, 88-96.	2.7	8
92	Reductions in telemetry order duration do not reduce telemetry utilization. <i>Journal of Hospital Medicine</i> , 2014, 9, 795-796.	1.4	7
93	A case of spontaneous coronary artery dissection diagnosed by coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 88-89.	1.3	7
94	Electronic Health Record Data Quality Issues Are Not Remedied by Increasing Granularity of Diagnosis Codes. <i>JAMA Cardiology</i> , 2019, 4, 465.	6.1	7
95	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006019.	2.2	7
96	Application of the New Cholesterol Guidelines. <i>New England Journal of Medicine</i> , 2014, 371, 77-79.	27.0	6
97	The Potential and Pitfalls of Coronary Artery Calcium Scoring. <i>JAMA Cardiology</i> , 2022, 7, 11.	6.1	6
98	Cardiovascular care for older adults: hypertension and stroke in the older adult. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 373-9.	0.2	6
99	Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 383-392.	1.9	6
100	Prevalence, treatment, and control of severe hyperlipidemia. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100079.	3.0	5
101	Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. <i>Clinical Cardiology</i> , 2021, 44, 955-962.	1.8	5
102	Underdiagnosis of familial hypercholesterolaemia: innovation is overdue. <i>European Heart Journal</i> , 2022, 43, 3255-3257.	2.2	5
103	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. <i>American Heart Journal</i> , 2014, 167, 466-471.	2.7	4
104	Evolving Approaches for Statins in Primary Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1981.	7.4	4
105	Impediments to Implementing Guideline-Directed Medical Therapies. <i>JAMA Cardiology</i> , 2019, 4, 830.	6.1	4
106	TRIGLYCERIDES AS A RISK FACTOR FOR CORONARY HEART DISEASE: WHAT MEASURE AND WHAT CUTOFF?. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1865.	2.8	4
107	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	1.5	4
108	Sticky Issues for Adherence in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1555-1557.	2.8	3

#	ARTICLE	IF	CITATIONS
109	Statins Work, but Only in People Who Take Them. <i>JAMA Cardiology</i> , 2019, 4, 214.	6.1	3
110	County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100118.	3.0	3
111	Is Coronary Calcium Scanning the “Secret Sauce” for Affordable Atherosclerotic Cardiovascular Disease Primary Prevention Trials?. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1017-1019.	5.3	3
112	Patients Affected by Changes to Hypertension Guideline”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 846.	7.4	2
113	Response to Letter Regarding Article, “Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease”: <i>Circulation</i> , 2015, 132, e203.	1.6	2
114	RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 59.	2.8	2
115	Some patient interventions increased thiazide prescriptions and improved blood pressure control. <i>Annals of Internal Medicine</i> , 2019, 170, JC46.	3.9	2
116	High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020, 5, 692.	6.1	2
117	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , 2021, 44, 863-870.	1.8	2
118	Extrapolating Survival From Randomized Clinical Trial Data”Possibilities and Caution. <i>JAMA Cardiology</i> , 2021, 6, 1305.	6.1	2
119	Transforming the Paradigm for Lipid Lowering. <i>JAMA Cardiology</i> , 2021, , .	6.1	2
120	Chronic Stress and Risks for Myocardial Infarction in U.S. Adults. <i>Innovation in Aging</i> , 2020, 4, 394-395.	0.1	2
121	Communicating the Benefits of Vaccination in Light of Potential Risks. <i>JAMA Cardiology</i> , 2022, 7, 612.	6.1	2
122	In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. <i>Annals of Internal Medicine</i> , 2016, 164, JC66.	3.9	1
123	Open Access Platforms for Sharing Clinical Trial Data”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 666.	7.4	1
124	The Complexities of Hypertension. <i>JAMA Cardiology</i> , 2017, 2, 389.	6.1	1
125	Regional Differences in Secondary Prevention Therapy”Geography Should Not Be Destiny. <i>JAMA Cardiology</i> , 2019, 4, 873.	6.1	1
126	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	2.8	1

#	ARTICLE	IF	CITATIONS
127	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. <i>Atherosclerosis</i> , 2021, 321, 1-7.	0.8	1
128	The Cumulative Impact of Chronic Stressors on Risks for Myocardial Infarction in U.S. Older Adults. <i>Psychosomatic Medicine</i> , 2021, Publish Ahead of Print, 987-994.	2.0	1
129	A High-Dose Continuous Haloperidol Infusion Successfully Controlled Intractable Terminal Delirium (748). <i>Journal of Pain and Symptom Management</i> , 2011, 41, 301-302.	1.2	0
130	PATIENT PERCEPTIONS AND MANAGEMENT OF CHOLESTEROL AMONG INDIVIDUALS WITH OR WITHOUT DIABETES IN COMMUNITY PRACTICE: RESULTS FROM THE PALM REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1710.	2.8	0
131	PRACTICE-LEVEL VARIATION IN STATIN USE AND LDL-C CONTROL IN THE UNITED STATES: RESULTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1706.	2.8	0
132	Questioning the Benefit of Statins for Low-Risk Populationsâ€”Medical Misinformation or Scientific Evidence?â€”Reply. <i>JAMA Cardiology</i> , 2020, 5, 233.	6.1	0
133	Choosing an Initial Therapeutic Approach for Hypertensionâ€”Time for a Fixed-Dose Combination First?. <i>JAMA Cardiology</i> , 2020, 5, 1217.	6.1	0
134	Teaching Old Treatments New Tricks. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009725.	3.9	0
135	Heroism in the Face of the COVID-19 Pandemic. <i>JAMA Cardiology</i> , 2020, 5, 1163.	6.1	0
136	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. <i>American Journal of Cardiology</i> , 2021, 142, 83-90.	1.6	0
137	The Changing Profile of Autopsies in Cardiovascular Deaths in the United States, 2003-2018. <i>American Journal of Cardiology</i> , 2021, 140, 150-151.	1.6	0
138	Statin Eligibility Under American and European Cholesterol Guidelinesâ€”Reply. <i>JAMA Cardiology</i> , 2017, 2, 460.	6.1	0
139	Limitations of Observational Studies for Aspirin in Primary Prevention and the Need for Randomized Trials. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, e220079.	2.5	0